Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Masters of Immunology

  • Masters of Immunology
    The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
    Thomas A. Waldmann
    Cancer Immunol Res March 1 2015 3 (3) 219-227; DOI:10.1158/2326-6066.CIR-15-0009

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Peptide/MHC Tetramer–Based Sorting of CD8+ T Cells to a Leukemia Antigen Yields Clonotypes Drawn Nonspecifically from an Underlying Restricted Repertoire
    Sally A. Hunsucker, Colleen S. McGary, Benjamin G. Vincent, Atim A. Enyenihi, Jennifer P. Waugh, Karen P. McKinnon, Lisa M. Bixby, Patricia A. Ropp, James M. Coghill, William A. Wood, Don A. Gabriel, Stefanie Sarantopoulos, Thomas C. Shea, Jonathan S. Serody, Gheath Alatrash, Tania Rodriguez-Cruz, Gregory Lizée, Adam S. Buntzman, Jeffrey A. Frelinger, Gary L. Glish and Paul M. Armistead
    Cancer Immunol Res March 1 2015 3 (3) 228-235; DOI:10.1158/2326-6066.CIR-14-0001

    Hunsucker, McGary, Vincent, and colleagues report that low-frequency, antigen-specific T-cell responses may be specifically tested using tetramer-based, single-cell sorting and sequencing of the antigen-specific TCRβ clonotypes, and then mapping them onto a patient's TCRβ to quantify antigen-driven clonal expansion.

Priority Brief

  • Priority Brief | AuthorChoice
    Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
    Alfred Zippelius, Jens Schreiner, Petra Herzig and Philipp Müller
    Cancer Immunol Res March 1 2015 3 (3) 236-244; DOI:10.1158/2326-6066.CIR-14-0226

    Zippelius and colleagues report that anti-CD40 treatment induces T cell– and IFNγ-dependent PD-L1 expression on tumor-infiltrating monocytes and macrophages. Consequently, the combination of anti-CD40 therapy with PD-1/PD-L1 blockade elicits effective tumor rejection in mouse models of breast and colon cancer.

Research Articles

  • Research Articles
    CD25 Identifies a Subset of CD4+FoxP3− TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer
    Ronald J. deLeeuw, David R. Kroeger, Sara E. Kost, Pheh-Ping Chang, John R. Webb and Brad H. Nelson
    Cancer Immunol Res March 1 2015 3 (3) 245-253; DOI:10.1158/2326-6066.CIR-14-0146

    deLeeuw and colleagues analyzed tumor-infiltrating lymphocytes (TIL) in primary high-grade serous ovarian cancer and discovered a novel subset of CD4+ TIL that are strongly associated with patient survival and hence warrant consideration as effector cells for immunotherapy.

  • Research Articles
    Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
    Jeremy Bastid, Anne Regairaz, Nathalie Bonnefoy, Cécile Déjou, Jérôme Giustiniani, Caroline Laheurte, Stéphanie Cochaud, Emilie Laprevotte, Elisa Funck-Brentano, Patrice Hemon, Laurent Gros, Nicole Bec, Christian Larroque, Gilles Alberici, Armand Bensussan and Jean-François Eliaou
    Cancer Immunol Res March 1 2015 3 (3) 254-265; DOI:10.1158/2326-6066.CIR-14-0018

    Bastid and colleagues show that CD39 is highly expressed on tumor-infiltrating lymphocytes, tumor stroma, but also on tumor cells; treatment with CD39 inhibitors or blocking antibody alleviated the tumor-induced inhibition of T-cell proliferation and increased CTL- and NK cell–mediated cytotoxicity.

  • Research Articles
    Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
    Hong Xu, Ming Cheng, Hongfen Guo, Yuedan Chen, Morgan Huse and Nai-Kong V. Cheung
    Cancer Immunol Res March 1 2015 3 (3) 266-277; DOI:10.1158/2326-6066.CIR-14-0230-T

    Xu and colleagues describe a novel, fully humanized, aglycosylated bispecific antibody targeting GD2 pentasaccharide with femtomolar cytotoxic EC50 against cancer cell lines that activates T cells in situ, drives intravenous T cells and monocytes to infiltrate tumor stroma, and ablates neuroblastoma and melanoma xenografts.

  • Research Articles
    Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
    Rachel Lubong Sabado, Anna Pavlick, Sacha Gnjatic, Crystal M. Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, John P. Vasilakos, Linda Rolnitzsky, Judith D. Goldberg, John Mandeli, Sylvia Adams, Achim Jungbluth, Linda Pan, Ralph Venhaus, Patrick A. Ott and Nina Bhardwaj
    Cancer Immunol Res March 1 2015 3 (3) 278-287; DOI:10.1158/2326-6066.CIR-14-0202

    Sabado, Pavlick, and colleagues show that NY-ESO-1 protein in Montanide with or without topical resiquimod is safe, well-tolerated, and induces antibody and CD4 T-cell responses in most patients, but the addition of topical resiquimod is not sufficient to induce consistent NY-ESO-1–specific CD8 T-cell responses.

  • Research Articles
    Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
    Douglas B. Johnson, Christine M. Lovly, Marisa Flavin, Katherine S. Panageas, Gregory D. Ayers, Zhiguo Zhao, Wade T. Iams, Marta Colgan, Sarah DeNoble, Charles R. Terry, Elizabeth G. Berry, A. John Iafrate, Ryan J. Sullivan, Richard D. Carvajal and Jeffrey A. Sosman
    Cancer Immunol Res March 1 2015 3 (3) 288-295; DOI:10.1158/2326-6066.CIR-14-0207

    Johnson, Lovly, and colleagues performed a retrospective analysis of clinical outcomes following immunotherapy on 229 patients with melanoma with or without NRAS mutations and report that NRAS mutations in advanced melanoma correlate with increased benefit from immune-based therapies compared with other genetic subtypes.

  • Research Articles
    Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
    Marina Moskalenko, Michael Pan, Yichun Fu, Ellen H. de Moll, Daigo Hashimoto, Arthur Mortha, Marylene Leboeuf, Padmini Jayaraman, Sebastian Bernardo, Andrew G. Sikora, Jedd Wolchok, Nina Bhardwaj, Miriam Merad and Yvonne Saenger
    Cancer Immunol Res March 1 2015 3 (3) 296-304; DOI:10.1158/2326-6066.CIR-14-0120

    Moskalenko, Pan, and colleagues show in a B16 melanoma model that tumor clearance from the combined regimen of cytotoxic doses of cyclophosphamide and an antibody targeting melanoma differentiation antigen tyrosine-related protein 1 requires Fcγ receptors and innate CD90+NK1.1− lymphocytes, not classical NK cells.

Back to top
PreviousNext
Cancer Immunology Research: 3 (3)
March 2015
Volume 3, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Masters of Immunology
  • Cancer Immunology Miniatures
  • Priority Brief
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement